Rose McNulty

ED law enforcement interactions affect survivors of violence and immigrant patients, emphasizing training and advocacy.

Methylprednisolone was more effective in treating thymoma compared with docetaxel but adverse effects were more common.

Zanidatamab shows promise in extending survival for patients with HER2-positive biliary tract cancer, marking a significant breakthrough in treatment options.

Asian women with breast cancer receiving chemotherapy had the highest persistent chemotherapy-induced alopecia (PCIA) incidence and alopecia-related distress vs their White, Black, and Hispanic or Latino peers.

This week, we look at 5 key health care changes the Trump Administration made in 2025, changes to the immunization schedule, and new research on telehealth accessibility.

Mass spectrometry technology identified proteomic biomarkers of IPF, but more work will be needed to fully translate these findings to the clinic.

Multidisciplinary care helps manage cardiac risks in breast cancer, allowing patients to continue treatment safely, says Eric H. Yang, MD.

Patients with myasthenia gravis experience significantly higher rates of urinary incontinence and overactive bladder symptoms, impacting their quality of life.

Population demographics and prevention efforts are key drivers of influenza burden, according to Marco del Riccio, MD.

Traditional Chinese medicine relies on nonlinear, unstructured data, but a new report suggests its practitioners can still benefit from machine learning, including in the treatment of idiopathic pulmonary fibrosis.

DeFi trial results show that continuous nirogacestat provides durable tumor control, ongoing shrinkage, sustained symptom improvement, and a stable safety profile over several years.

Top articles in non–small cell lung cancer (NSCLC) include FDA approvals, improved outcomes due to certain treatments, and updated data presented at conferences.

Scott Soefje, PharmD, outlines proactive financial screening, flexible payment models, and stronger academic-community partnerships for advanced cancer care.

Acute exacerbations of chronic rhinosinusitis are poorly defined and often overtreated, calling for standardized diagnostic criteria and more evidence-based management.

The most-read content for HIV focused on funding cuts to HIV aid and research and satisfaction with telemedicine for HIV care.

The most-read articles focused on soft tissue sarcoma research, including innovative biomarkers, treatment strategies, and multidisciplinary care challenges.

The 2025 Community Oncology Conference, hosted by COA, reflected a commitment to patient-centered care, access, and innovation in community oncology.

The top ophthalmology content included FDA approvals, FDA complete response letters, and new associations between cataracts and antioxidant index.

In the EPCORE DLBCL-3 study, fixed-duration epcoritamab monotherapy delivered deep, durable responses with manageable toxicity in older, chemotherapy-ineligible patients with LBCL.

A reimbursable, team-based remote blood pressure monitoring program significantly improved hypertension control in patients with multiple chronic conditions.

Respiratory syncytial virus (RSV) remains a leading cause of acute bronchitis in children, but new research may enable earlier intervention.

In-home step training for multiple sclerosis showed no improvement in ankle proprioception or muscle performance, highlighting challenges in exercise adherence.

Explore the latest breakthroughs in allergy treatments, including FDA approvals and emerging therapies that enhance patient care and address systemic challenges.

Chronic inducible cold urticaria is rare, but a new study suggests it can have significant impacts on patients’ daily lives.

Our top 5 heart failure content of 2025 include FDA approvals, GDMT optimization, risk markers like LBBB and SDOH, and value-based care models improving outcomes in heart failure.

Scott Soefje, PharmD, MBA, BCOP, of Mayo Clinic, discusses how payer-provider collaboration and pharmacist-led management can help improve oncology care.

Our conference coverage featured updates on clinical trials testing new treatments for NSCLC, bladder cancer, and breast cancer.

The FDA approves Wegovy, the first oral GLP-1 pill, offering a new weight loss solution for those struggling with obesity and overweight.

With a follow-up of up to 6 years, the median progression-free survival for long-term extension participants was 52.5 months.

The benefit of trabectedin plus olaparib to all-comers with soft tissue sarcoma was marginal, but the response was more pronounced in certain subgroups.